Q32 Bio combines exceptional fundamental quality, a perfect earnings-beat streak, and roughly 133% modeled upside to its analyst target with momentum sitting right at the engine's pass/fail gate and a short-squeeze setup the engine still flags as needing validation.
Thesis pillars
- High Quality Compounder Fundamentals→Stable
- Large Upside To Analyst Target→Stable
- Momentum Right At The Gate Threshold→Stable
- +2 more pillars — see the Why tab for full reasoning
Q32 Bio Inc. (QTTB) Stock Analysis
Oversold Bounce setup · Temporary headwind edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $8.27, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $39.60 vs price $8.27 — ratio 4.8×). Rejected, falling back to technical TP.; Market cap $246M below $400M minimum.
Q32 Bio is a clinical-stage biotechnology company developing bempikibart, an anti-IL-7Rα monoclonal antibody for alopecia areata, following Phase 2a trials showing greater hair regrowth versus placebo. The company has no approved products or product revenue and sold its ADX-097... Read more
Hold if already holding. Not a fresh buy at $8.27, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $39.60 vs price $8.27 — ratio 4.8×). Rejected, falling back to technical TP.; Market cap $246M below $400M minimum. Chart setup: Oversold RSI 28, near Bollinger lower, volume surge. Market cap $246M below $400M minimum. Not in investable universe. Score 6.6/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Q32 Bio Inc.
About Q32 Bio Inc.
Q32 Bio's lead program, bempikibart, is advancing through the open-label Part B of the SIGNAL-AA Phase 2a trial in alopecia areata, with 33 patients enrolled and 36-week topline data expected in mid-2026; the FDA granted the drug Fast Track designation in April 2025. The company has no approved products and no product revenue, reporting net income of $29.8 million for fiscal 2025 driven entirely by one-time collaboration revenue from an amendment with Amgen rather than commercial sales.
Q32 Bio has generated no product revenue to date and funds operations through private equity and debt financings, cash on hand, and one-time payments from partners; it expects existing cash plus proceeds from a February 2026 registered direct offering and guaranteed near-term Akebia milestones to fund operations into the fourth quarter of 2027. Bempikibart itself is developed under an exclusive license from Bristol-Myers Squibb, under which Q32 paid an $8 million upfront fee and owes up to $49 million in development and regulatory milestones per indication, up to $215 million in commercial milestones, and tiered royalties up to 10% of net sales. The company relies on third-party CDMOs and CROs to manufacture bempikibart and run its clinical trials rather than owning commercial-scale manufacturing capacity.
Show full overview
Bempikibart's binary trial risk is not hypothetical: in the SIGNAL-AD Phase 2a trial for atopic dermatitis, the same drug hit its endpoint in the smaller Part A cohort but missed the primary endpoint in the 106-patient Part B cohort, and Q32 subsequently narrowed its focus to alopecia areata alone. With no other clinical-stage franchise beyond the early-stage ADX-096 complement platform retained after the Akebia divestiture, the mid-2026 SIGNAL-AA Part B readout in 33 patients functions as a near-single-asset catalyst for a company with no approved products or ongoing commercial revenue.
See also: Healthcare · Biotechnology
From Q32 Bio Inc.'s most recent 10-K filing, extracted August 2, 2026.
Recent developments
updated 2026-10-01Recent Developments — Q32 Bio Inc.
Latest news
- NEWS QTTB|Q32 Bio Inc|Price:14.570|Chg%:-1.140 - TradingKey — TradingKey neutral
- NEWS QTTB|Q32 Bio Inc|Price:15.670|Chg%:+0.460 - TradingKey — TradingKey neutral
- NEWS QTTB|Q32 Bio Inc|Price:15.670|Chg%:+0.460 - tradingkey.com — tradingkey.com neutral
- NEWS Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade - qz.com — qz.com neutral
- NEWS H.C. Wainwright Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $36 - Moomoo — Moomoo positive
Generated 2026-10-01T11:52:00Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $8.27, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $39.60 vs price $8.27 — ratio 4.8×). Rejected, falling back to technical TP.; Market cap $246M below $400M minimum. Chart setup: Oversold RSI 28, near Bollinger lower, volume surge. Market cap $246M below $400M minimum. Not in investable universe. Target $14.26 (+72.4%), stop $7.69 (−7.5%), A.R:R 0.0:1. Score 6.6/10, moderate confidence.
Take-profit target: $14.26 (+72.4% upside). Target $14.26 (+72.4%), stop $7.69 (−7.5%), A.R:R 0.0:1. Stop-loss: $7.69.
DATA_ISSUE: analyst_target_implausible (raw $39.60 vs price $8.27 — ratio 4.8×). Rejected, falling back to technical TP.; Market cap $246M below $400M minimum.
Q32 Bio Inc. trades at a P/E of 2.3 (forward -8.1). TrendMatrix value score: 8.3/10. Verdict: Hold.
12 analysts cover QTTB with a consensus score of 4.2/5. Average price target: $40.
What does Q32 Bio Inc. do?Q32 Bio is a clinical-stage biotechnology company developing bempikibart, an anti-IL-7Rα monoclonal antibody for...
Q32 Bio is a clinical-stage biotechnology company developing bempikibart, an anti-IL-7Rα monoclonal antibody for alopecia areata, following Phase 2a trials showing greater hair regrowth versus placebo. The company has no approved products or product revenue and sold its ADX-097 complement-inhibitor program to Akebia Therapeutics in November 2025, retaining bempikibart and its early-stage ADX-096 platform.